Source-grounded facts extracted from INSMED Inc's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
INSMED Inc reported the first quarter ended March 31, 2026 results: revenue $306.0 Million. Guidance reaffirmed.
“99.1) --- EX-99.1 2 ef20072589_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update — Total Company Revenues of $306.0 Million for the First Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $207.9 Million for the First Quarter of 2026, Reflecting 44% Growth Over the Fourth Quarter of 2025 — —”
J. Drayton Wise resigned as Chief Commercial Officer at INSMED Inc.
“On April 16, 2025, J. Drayton Wise notified Insmed Incorporated (the “Company”) of his decision to resign from his position as the Company’s Chief Commercial Officer for personal and medical reasons, effective immediately.”
Alfred Altomari departed as Director at INSMED Inc.
“On February 18, 2025, Alfred Altomari notified the board of directors (the “Board”) of the Company that he will not stand for re-election to the Board upon the expiration of his current term as a Class I director, which occurs at the Company’s 2025 Annual Meeting of Shareholders (the “Annual Meeting”).”
INSMED Inc shareholders approved Approval of Amendment No. 1 to the Insmed Incorporated Amended and Restated 2019 Incentive Plan.
“Proposal 4. Approval of Amendment No. 1 to the Insmed Incorporated Amended and Restated 2019 Incentive Plan. By the following vote, shareholders approved Amendment No. 1 to the 2019 Incentive Plan: For Against Abstentions Broker Non-Votes 122,169,823 6,589,414 56,760 10,923,081”
INSMED Inc shareholders approved Ratification of the Appointment of an Independent Registered Public Accounting Firm at the 2024-12-31 meeting.
“Proposal 3. Ratification of the Appointment of an Independent Registered Public Accounting Firm. By the following vote, shareholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024: For Against Abstentions 135,507,026 4,170,279 61,773”
INSMED Inc shareholders approved Advisory Vote on the 2023 Compensation of Named Executive Officers.
“Proposal 2. Advisory Vote on the 2023 Compensation of Named Executive Officers. By the following vote, shareholders approved, on an advisory, non-binding basis, the compensation of our named executive officers, as disclosed in the Proxy Statement: For Against Abstentions Broker Non-Votes 120,643,045 8,076,144 96,808 10,923,081”
INSMED Inc shareholders approved Election of Four Class III Directors.
“Proposal 1. Election of Four Class III Directors. By the following votes, shareholders elected David R. Brennan, Leo Lee, Carol A. Schafer, and Melvin Sharoky, M.D. to serve as Class III directors until the Company’s 2027 Annual Meeting of Shareholders: For Withheld Broker Non-Votes David R. Brennan 120,537,761 8,278,236 10,923,081 Leo Lee 125,634,442 3,181,555 10,923,081 Carol A. Schafer 113,910,394 14,905,603 10,923,081 Melvin Sharoky, M.D. 117,140,717 11,675,280 10,923,081”
INSMED Inc updated its the first quarter ended March 31, 2024 guidance (reaffirmed).
“On May 9, 2024, Insmed Incorporated (the “Company”) issued a press release regarding its financial results for the three months ended March 31, 2024.”
INSMED Inc reported financial results for the fourth quarter and full year ended December 31, 2023.
“On February 22, 2024, Insmed Incorporated issued a press release regarding its financial results for the three months and fiscal year ended December 31, 2023.”
INSMED Inc terminated Prior Agreement with Leerink Partners LLC (effective 2024-02-22).
“On February 22, 2024, in connection with entry into the Agreement described under Item 1.01 above, the Company and Leerink mutually agreed to terminate the Prior Agreement, which termination became effective on February 22, 2024.”
INSMED Inc entered into Sales Agreement with Leerink Partners LLC valued at up to $500,000,000 (effective 2024-02-22).
“On February 22, 2024, Insmed Incorporated (the “Company”) entered into a Sales Agreement (the “Agreement”) with Leerink Partners LLC, as agent (“Leerink”), under which the Company may offer and sell its common stock, par value $0.01 per share, from time to time having an aggregate offering price of up to $500,000,000 (the “Shares”) during the term of the Agreement through Leerink, acting as agent.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.